Metformin therapy associated with survival benefit in lung cancer patients with diabetes

Oncotarget

Volumn 7, Issue 23, 2016, Pages 35437-35445

  Wan, Guoxing ^a   Yu, Xiongjie ^a   Chen, Ping ^a   Wang, Xianhe ^a   Pan, Dongfeng ^a   Wang, Xuanbin ^a   Li, Linjun ^a   Cai, Xiaojun ^a   Cao, Fengjun ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Diabetes; Lung Cancer; Meta analysis; Metformin; Survival

Indexed keywords

METFORMIN; ANTIDIABETIC AGENT;

ARTICLE; ASIAN; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CAUCASIAN; CHEMORADIOTHERAPY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; EVIDENCE BASED MEDICINE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; RISK REDUCTION; SMALL CELL LUNG CANCER; COMPLICATION; DIABETIC COMPLICATION; LUNG TUMOR; MORTALITY;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; LUNG NEOPLASMS; METFORMIN;

EID: 84973621746     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8881     Document Type: Article

References (43)

1. Richardson LC and Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol. 2005; 2:48-53
2. Coughlin SS, Calle EE, Teras LR, Petrelli J and Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159:1160-7
3. Sayed R, Saad AS, Wakeel LE, Elkholy E and Badary O. Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study. Asian Pac J Cancer Prev. 2015; 16:6621-6
4. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010; 60:207-21
5. Yin M, Zhou J, Gorak EJ and Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and metaanalysis. Oncologist. 2013; 18:1248-55
6. Coperchini F, Leporati P, Rotondi M and Chiovato L. Expanding the therapeutic spectrum of metformin: from diabetes to cancer. J Endocrinol Invest. 2015; 38:1047-55
7. Moiseeva O, Deschenes-Simard X, Pollak M and Ferbeyre G. Metformin, aging and cancer. Aging (Albany NY). 2013; 5:330-1. doi: 10.18632/aging.100556
8. Anisimov VN. Metformin and rapamycin are master-keys for understanding the relationship between cell senescent, aging and cancer. Aging (Albany NY). 2013; 5:337-8. doi: 10.18632/aging.100561
9. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, Jang WG, Cho WJ, Ha J, Lee IK, Lee CH and Choi HS. Metformin inhibits hepatic gluconeogenesis through AMPactivated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008; 57:306-14
10. Staels B. Metformin and pioglitazone: Effectively treating insulin resistance. Curr Med Res Opin. 2006; 22 Suppl 2:S27-37
11. Bulcao C, Ribeiro-Filho FF, Sanudo A and Roberta FS. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Am J Cardiovasc Drugs. 2007; 7:219-24
12. Chen YQ and Chen G. Combined therapeutic effect and molecular mechanisms of metformin and cisplatin in human lung cancer xenografts in nude mice. J Cancer Res Ther. 2015; 11:324-30
13. Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF and Bernards R. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer. 2015; 136:1434-44
14. Zhao Z, Cheng X, Wang Y, Han R, Li L, Xiang T, He L, Long H, Zhu B and He Y. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. Plos One. 2014; 9:e95884
15. Han D, Li SJ, Zhu YT, Liu L and Li MX. LKB1/AMPK/mTOR signaling pathway in non-small-cell lung cancer. Asian Pac J Cancer Prev. 2013; 14:4033-9
16. Storozhuk Y, Hopmans SN, Sanli T, Barron C, Tsiani E, Cutz JC, Pond G, Wright J, Singh G and Tsakiridis T. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br J Cancer. 2013; 108:2021-32
17. Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, Yao B, Xie K, Li LH, Dong H, Gao F, Zhao F, Hou JM, Su JM and Liu JY. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. Cancer-Am Cancer Soc. 2011; 117:5103-11
18. Xu T, Liang G, Yang L and Zhang F. Prognosis of small cell lung cancer patients with diabetes treated with metformin. Clin Transl Oncol. 2015; 17:819-24
19. Ahmed I, Ferro A, Cohler A, Langenfeld J, Surakanti SG, Aisner J, Zou W, Haffty BG and Jabbour SK. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J Thorac Dis. 2015; 7:346-55
20. Tian RH, Zhang YG, Wu Z, Liu X, Yang JW and Ji HL. Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis. Clin Transl Oncol. 2015
21. Kong F, Gao F, Liu H, Chen L, Zheng R, Yu J, Li X, Liu G and Jia Y. Metformin use improves the survival of diabetic combined small-cell lung cancer patients. Tumour Biol. 2015; 36:8101-6
22. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA and Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012; 35:299-304
23. Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, LeRoith D and Wisnivesky JP. Survival of patients with stage IV lung cancer with diabetes treated with metformin. Am J Respir Crit Care Med. 2015; 191:448-54
24. Chen H, Yao W, Chu Q, Han R, Wang Y, Sun J, Wang D, Wang Y, Cao M and He Y. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes. Cancer Lett. 2015; 369:97-102
25. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A and Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. Bmc Cancer. 2012; 12:410
26. Xu H, Aldrich MC, Chen Q, Liu H, Peterson NB, Dai Q, Levy M, Shah A, Han X, Ruan X, Jiang M, Li Y, Julien JS, Warner J, Friedman C and Roden DM, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. J Am Med Inform Assoc. 2015; 22:179-91
27. Wink KC, Belderbos JS, Dieleman EM, Rossi M, Rasch CR, Damhuis RA, Houben RM and Troost EG. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol. 2016; 118:453-9
28. Wang Y, Lin B, Wu J, Zhang H and Wu B. Metformin inhibits the proliferation of A549/CDDP cells by activating p38 mitogen-activated protein kinase. Oncol Lett. 2014; 8:1269-74
29. Ding L, Liang G, Yao Z, Zhang J, Liu R, Chen H, Zhou Y, Wu H, Yang B and He Q. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget. 2015; 6:36441-55. doi: 10.18632/oncotarget.5541
30. Vujic I, Sanlorenzo M, Posch C, Esteve-Puig R, Yen AJ, Kwong A, Tsumura A, Murphy R, Rappersberger K and Ortiz-Urda S. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget. 2015; 6:969-78. doi: 10.18632/oncotarget.2824
31. Xiao Z, Sperl B, Ullrich A and Knyazev P. Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status. Oncotarget. 2014; 5:12877-90. doi: 10.18632/oncotarget.2657
32. Li L, Huang W, Li K, Zhang K, Lin C, Han R, Lu C, Wang Y, Chen H, Sun F and He Y. Metformin attenuates gefitinibinduced exacerbation of pulmonary fibrosis by inhibition of TGF-beta signaling pathway. Oncotarget. 2015; 6:43605-19. doi: 10.18632/oncotarget.6186
33. Karnevi E, Said K, Andersson R and Rosendahl AH. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. Bmc Cancer. 2013; 13:235
34. Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ and Dennis PA. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila). 2013; 6:801-10
35. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A and Szabo E. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014; 7:867-85
36. Suissa S and Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012; 35:2665-73
37. Zhang H, Gao C, Fang L, Zhao HC and Yao SK. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2013; 48:78-87
38. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25:603-5
39. Higgins JP, Thompson SG, Deeks JJ and Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327:557-60
40. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22:719-48
41. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177-88
42. Begg CB and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50:1088-101
43. Egger M, Davey SG, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629-34